LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership with GSK, to evaluate the potential of combining LIXTE’s LB-100 with GSK’s PD-1-blocking antibody, dostarlimab-gxly, in treating ovarian clear cell carcinoma (OCCC). The University of Texas MD Anderson Cancer Center is conducting this trial, with LIXTE providing […]